Last reviewed · How we verify
L-Tyrosine 500 Mg
L-Tyrosine 500 Mg is a Small molecule drug developed by Direction Centrale du Service de Santé des Armées. It is currently in Phase 1 development.
At a glance
| Generic name | L-Tyrosine 500 Mg |
|---|---|
| Sponsor | Direction Centrale du Service de Santé des Armées |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Anaemia
- Neutropenia
- Fatigue
- Cough
- Thrombocytopenia
- Pyrexia
- Constipation
- Vomiting
- Rash
- Headache
Key clinical trials
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC (PHASE2)
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (PHASE1, PHASE2)
- Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (PHASE2)
- An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. (PHASE2)
- A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Tyrosine 500 Mg CI brief — competitive landscape report
- L-Tyrosine 500 Mg updates RSS · CI watch RSS
- Direction Centrale du Service de Santé des Armées portfolio CI
Frequently asked questions about L-Tyrosine 500 Mg
What is L-Tyrosine 500 Mg?
L-Tyrosine 500 Mg is a Small molecule drug developed by Direction Centrale du Service de Santé des Armées.
Who makes L-Tyrosine 500 Mg?
L-Tyrosine 500 Mg is developed by Direction Centrale du Service de Santé des Armées (see full Direction Centrale du Service de Santé des Armées pipeline at /company/direction-centrale-du-service-de-sant-des-arm-es).
What development phase is L-Tyrosine 500 Mg in?
L-Tyrosine 500 Mg is in Phase 1.
What are the side effects of L-Tyrosine 500 Mg?
Common side effects of L-Tyrosine 500 Mg include Diarrhoea, Nausea, Anaemia, Neutropenia, Fatigue, Cough.